Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267644 | 0.88 | ALDH1A1 (0.54) | ALDH1A1POLBKMT2AMAPTACACB | |
| SCHEMBL12230967 | 0.87 | ALDH1A1 (0.44) | ALDH1A1POLBKMT2AMAPTACACB | |
| SCHEMBL12230966 | 0.87 | ALDH1A1 (0.44) | ALDH1A1POLBKMT2AMAPTACACB | |
| SCHEMBL18954564 | 0.86 | ALDH1A1 (0.43) | ALDH1A1POLBKMT2AMAPTACACB | |
| SCHEMBL25368994 | 0.84 | CYP1A2 (0.41) | ALDH1A1KMT2AMAPTCYP1A2MAPK1 | |
| SCHEMBL29620241 | 0.84 | KDM4E (0.41) | ALDH1A1POLBMAPTCYP1A2MAPK1 | |
| SCHEMBL2567865 | 0.82 | CYP1A2 (0.40) | ALDH1A1MAPTCYP1A2MAPK1NPC1 | |
| SCHEMBL3714376 | 0.82 | CYP1A2 (0.40) | ALDH1A1POLBMAPTCYP1A2NPC1 | |
| SCHEMBL14336034 | 0.82 | CYP3A4 (0.44) | ALDH1A1POLBKMT2AMAPTMAPK1 | |
| SCHEMBL14351455 | 0.81 | LMNA (0.50) | ALDH1A1POLBKMT2AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844644-B1 | PROCESS FOR PREPARATION OF 4-METHYLOXAZOLE-5-CARBOXYLIC ESTER | DSM IP ASSETS BV (NL) | 2018-11-14 | — | — | EP | claimed |
| EP-2721015-B1 | PROCESS FOR 4-METHYLOXAZOLE-5-CARBOXAMIDE | DSM IP ASSETS BV (NL) | 2017-03-01 | — | — | EP | claimed |
| EP-2844644-A1 | A NEW PROCESS FOR PREPARATION OF 4-METHYLOXAZOLE-5-CARBOXYLIC ESTER | DSM IP Assets B.V. (NL) | 2015-03-11 | — | — | EP | claimed |
| US-8916715-B2 | Process for 4-methyloxazole-5-carboxamide | DSM IP ASSETS B.V. (NL) | 2014-12-23 | — | — | US | claimed |
| US-20140206880-A1 | PROCESS FOR 4-METHYLOXAZOLE-5-CARBOXAMIDE | DSM IP ASSETS B.V. (NL) | 2014-07-24 | — | — | US | claimed |
| EP-2721015-A1 | PROCESS FOR 4-METHYLOXAZOLE-5-CARBOXAMIDE | DSM IP Assets B.V. (NL) | 2014-04-23 | — | — | EP | claimed |
| WO-2013185976-A1 | A NEW PROCESS FOR PREPARATION OF 4-METHYLOXAZOLE-5-CARBOXYLIC ESTER | DSM IP ASSETS B.V. (NL) | 2013-12-19 | — | — | WO | claimed |
| WO-2012175304-A1 | PROCESS FOR 4-METHYLOXAZOLE-5-CARBOXAMIDE | DSM IP ASSETS B.V. (NL) | 2012-12-27 | — | — | WO | claimed |
| US-4772718-A | AMMONIA, 5-ALKOXYCARBONYL-4-METHYLOXAZOLE, ZIRCONIUM OXIDE OR HAFNIUM OXIDE CATALYST | HOFFMANN-LA ROCHE INC. (US) | 1988-09-20 | — | — | US | claimed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250145600-A1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | NOVARTIS AG (CH) | 2025-05-08 | — | — | US | disclosed |
| CN-116075498-B | Process for preparing oxazole compounds | 帝斯曼知识产权资产管理有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025037013-A1 | DIAGNOSTIC COMPOUNDS THAT BIND TO ALPHA-SYNUCLEIN | AC IMMUNE SA (CH) | 2025-02-20 | — | — | WO | disclosed |
| US-4360678-A | PLANT SAFENING AGENT | MONSANTO COMPANY (US) | 1982-11-23 | — | — | US | disclosed |
| EP-0064667-A1 | Process for the preparation of sulfoalkyl quaternary salts | Agfa-Gevaert AG (DE) | 1982-11-17 | — | — | EP | disclosed |
| EP-0055428-A1 | Bis-(3-sulfopropyl)ethers, process for their preparation and their use as alkylating agents for organic bases | Agfa-Gevaert AG (DE) | 1982-07-07 | — | — | EP | disclosed |
| US-4308390-A | Process for the production of sulphoalkyl quaternary salts | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1981-12-29 | — | — | US | disclosed |
| US-4303439-A | ANTIDOTES TO REDUCE HERBICIDAL INJURY | MONSANTO COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
| EP-0034279-A2 | Sulfoalkylating agents, process for their preparation and their use in the manufacture of quanternary sulfoalkyl salts | Agfa-Gevaert AG (DE) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145600-A1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | GLP1R, GPR119, GIPR | ALDH1A1 604/4885POLB 4289/4885KMT2A 850/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | ALDH1A1 3780/4885POLB 4664/4885KMT2A 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.